reviewing the role and efficacy of ruxolitinib in myelofibrosis ten years after its approval
Published 1 year ago • 247 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
1:52
the role of ruxolitinib in the treatment of early-stage myelofibrosis
-
1:18
novel approaches for the treatment of myelofibrosis: navitoclax ruxolitinib
-
2:54
ruxolitinib in the real world: myelofibrosis
-
5:12
ongoing clinical trials of ruxolitinib-based combinations in myelofibrosis
-
2:10
management of ruxolitinib failure in myelofibrosis
-
10:54
jakafi (ruxolitinib) the new medication of polycythemia vera and myelofibrosis. mechanism of action
-
6:44
how does jakafi® (ruxolitinib) work?
-
2:44
myelofibrosis: jenson shares his experience
-
2:05
adore: novel combinations with ruxolitinib for myelofibrosis
-
3:09
real-world data analysis of ruxolitinib in myelofibrosis
-
21:55
myelofibrosis: considering tp53 and post-mpn aml
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
1:16
the rationale for combining magrolimab with ruxolitinib in myelofibrosis
-
1:20
the impact of early ruxolitinib treatment on os in the comfort-i and comfort-ii studies
-
2:02
analyses from comfort trials of ruxolitinib for myelofibrosis
-
1:53
parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib
-
1:57
combined navitoclax and ruxolitinib therapy in r/r myelofibrosis
-
3:35
analysis from most: disease progression and leukemic transformation in lower-risk myelofibrosis
-
1:01
latest advances in myelofibrosis treatment
-
4:16
jak inhibitor selection & sequencing in myelofibrosis
-
1:46
how would the approval of luspatercept benefit the treatment landscape in myelofibrosis
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis